Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 4:35 pm Purchase | 13G | Tarsus Pharmaceuticals Inc. TARS | Paradigm Biocapital Advisors LP | 2,440,445 6.400% | 512,939 (+26.61%) | View |
| 2024-11-14 4:35 pm Purchase | 13G | Arcellx Inc. ACLX | Paradigm Biocapital Advisors LP | 4,800,000 8.900% | 1,141,376 (+31.20%) | View |
| 2024-11-14 4:35 pm Sale | 13G | COMPASS PATHWAYS PLC SPONSORED CMPS | Paradigm Biocapital Advisors LP | 2,320,000 3.300% | -1,105,988 (-32.28%) | View |
| 2024-11-14 4:34 pm Sale | 13G | Olema Pharmaceuticals Inc. OLMA | Paradigm Biocapital Advisors LP | 5,503,600 9.600% | -2,400,000 (-30.37%) | View |
| 2024-11-14 4:34 pm Purchase | 13G | Nuvalent Inc. NUVL | Paradigm Biocapital Advisors LP | 5,000,000 7.800% | 1,141,992 (+29.60%) | View |
| 2024-11-14 4:33 pm Sale | 13G | Vor Biopharma Inc. VOR | Paradigm Biocapital Advisors LP | 0 0.000% | -6,457,293 (Position Closed) | View |
| 2024-11-14 4:33 pm Sale | 13G | VIRIDIAN THERAPEUTICS INC VRDN | Paradigm Biocapital Advisors LP | 3,509,253 4.600% | -1,795,060 (-33.84%) | View |
| 2024-11-14 4:33 pm Sale | 13G | Disc Medicine Inc. IRON | Paradigm Biocapital Advisors LP | 1,497,720 5.040% | -888,137 (-37.23%) | View |
| 2024-11-14 4:32 pm Sale | 13G | BICYCLE THERAPEUTICS PLC BCYC | Paradigm Biocapital Advisors LP | 0 0.000% | -3,707,001 (Position Closed) | View |
| 2024-11-14 4:32 pm Sale | 13G | Autolus Therapeutics plc AUTL | Paradigm Biocapital Advisors LP | 0 0.000% | -12,611,335 (Position Closed) | View |
| 2024-11-14 4:32 pm Purchase | 13G | Y-MABS THERAPEUTICS INC YMAB | Paradigm Biocapital Advisors LP | 4,086,346 9.200% | 1,888,034 (+85.89%) | View |
| 2024-11-14 4:31 pm Purchase | 13G | Kura Oncology Inc. KURA | Paradigm Biocapital Advisors LP | 4,331,321 5.700% | 470,003 (+12.17%) | View |
| 2024-10-23 5:39 pm Purchase | 13G | Janux Therapeutics Inc. JANX | Paradigm Biocapital Advisors LP | 2,608,574 5.000% | 2,608,574 (New Position) | View |
| 2024-10-04 5:34 pm Purchase | 13G | PLIANT THERAPEUTICS INC PLRX | Paradigm Biocapital Advisors LP | 3,059,411 5.030% | 3,059,411 (New Position) | View |
| 2024-05-02 4:34 pm Purchase | 13G | Kura Oncology Inc. KURA | Paradigm Biocapital Advisors LP | 3,861,318 5.100% | 3,861,318 (New Position) | View |
| 2024-04-08 5:09 pm Purchase | 13G | Y-MABS THERAPEUTICS INC YMAB | Paradigm Biocapital Advisors LP | 2,198,312 5.020% | 2,198,312 (New Position) | View |
| 2024-02-14 5:57 pm Purchase | 13G | Arcellx Inc. ACLX | Paradigm Biocapital Advisors LP | 3,658,624 7.000% | 1,235,924 (+51.01%) | View |
| 2024-02-14 4:08 pm Purchase | 13G | Ambrx Biopharma Inc. AMAM | Paradigm Biocapital Advisors LP | 4,502,689 7.100% | 4,502,689 (New Position) | View |
| 2024-02-14 4:08 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Paradigm Biocapital Advisors LP | 3,176,743 5.500% | 859,109 (+37.07%) | View |
| 2024-02-14 4:08 pm Purchase | 13G | Autolus Therapeutics plc AUTL | Paradigm Biocapital Advisors LP | 12,611,335 7.200% | 2,512,751 (+24.88%) | View |